Phase I trial of elactocin
1996

Phase I Trial of Elactocin

Sample size: 33 publication Evidence: low

Author Information

Author(s): ES Newlands, GJS Rustin, MH Brampton

Primary Institution: Department of Medical Oncology, Charing Cross Hospital

Hypothesis

Elactocin is a novel anti-tumour antibiotic that may have significant activity against various cancers.

Conclusion

Elactocin has a unique toxicity profile with marked malaise and anorexia, and no effective dosing schedule was found to recommend for further trials.

Supporting Evidence

  • Elactocin was administered to 33 patients with advanced refractory cancer.
  • Profound anorexia and malaise were identified as dose-limiting toxicities.
  • No partial or complete responses were observed in the trial.

Takeaway

Elactocin is a new cancer drug that made patients feel very sick, so doctors decided not to use it anymore.

Methodology

Patients with advanced refractory cancer were treated with elactocin in various infusion schedules to determine toxicity and maximum tolerated dose.

Limitations

No pharmacology was performed due to interference from other substances in patient samples.

Participant Demographics

19 males and 14 females with a median age of 49 years.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication